Market OutlookPeripheral arterial disease (PAD) is a complex manifestation of underlying atherosclerotic disease and is severely undertreated. The failure of therapies to improve walking distance…
The treatment of chronic pain continues to provide unique challenges to physicians owing to the heterogeneity of pain pathophysiology within and across different chronic pain subtypes and the…
A variety of analgesic products are available to specialists managing postoperative pain in the United States, although the majority of these medicines are available as inexpensive generics…
DRG Epidemiology’s coverage of atopic dermatitis/atopic eczema (AD) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States,…
MARKET OUTLOOKThe lucrative HR-positive, HER2-negative breast cancer market in Europe is fast-moving and competitive. CDK4/6 inhibitors Ibrance (Pfizer), Kisqali (Novartis) and Verzenios (Eli Lilly…
MARKET OUTLOOK The treatment landscape for psoriasis in the top 5 European markets (France, Germany, Italy, Spain, UK) is extremely dynamic. Humira (AbbVie), Enbrel (Amgen), Stelara (Janssen), and…
MARKET OUTLOOK The European atopic dermatitis (AD) market has entered a new era. In 2017, IL-4/13 inhibitor Dupixent (Sanofi/Regeneron) became the first targeted biologic to be approved for…